Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue Market, Trends, Share, Size Research Report

Home
Pharmaceutical
Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue

Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue

Publisher Name » GBI Research

Published Date » 2012-06-25

GBI Research’s new report, “Emerging Pharmaceutical Market in Argentina – Domestic Pharmaceutical Companies Dominate the Market with More than 55% of the Industry Revenue” provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in Argentina. The report analyzes the overall pharma and clinical trials market in Argentina.

Furthermore, the report provides profiles for the leading pharmaceutical companies, Contract Research Organizations (CROs) and distributors; analyzes the macroeconomic environment; describes the healthcare regulations of Argentina and analyzes the strategic consolidations that shape the Argentine pharmaceutical market. This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Argentina is the third largest market for pharmaceuticals in Latin America. There are 230 registered laboratories and 110 manufacturing plants in Argentina and most of these are domestic. Over 80% of the laboratories and manufacturing plants are located in urban areas, especially in the province of Buenos Aires. The market has shown significant growth ever since the economic crisis during 2001-2002, due to the ageing population and high proportion of elderly people in the country’s population; growth in government healthcare expenditure; increased internal consumption of medicines and increasing prevalence of diseases which come under major therapy areas such as cardiovascular, Central Nervous System (CNS), gastrointestinal and metabolism, among others.

A similarly positive trend is expected in the future due to a number of facts such as increasing internal consumption, a rise in the elderly population favorable strategic consolidations and increasing government healthcare expenditure. GBI Research expects the market to exhibit double-digit growth during the period 2010–2015. GBI Research has analyzed the pharmaceutical market in Argentina and found that it is dominated by domestic pharmaceutical companies. Most of the domestic laboratories in Argentina are private and they explored the domestic market.

The prescription drugs’ market accounted for about 90% of the market. Despite issues relating to Intellectual Property (IP) laws, multinational pharmaceutical companies are expanding their market presence by acquiring small domestic laboratories and through licensing agreements. The Argentine pharmaceutical market is one of the top emerging markets which have shown an annual growth rate of up to 22% in recent years. The economic growth of the country has been above the global average and the healthcare sector’s expenditure accounted for approximately 10% of the country’s GDP, of which the government’s healthcare spending accounted for over 60%.

According to GBI Research’s analysis, Argentina is an attractive market for pharmaceuticals and clinical trials due to a number of factors, such as the aligned legal provisions by Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) (the principal regulatory body in Argentina) and Ministry of Health (MOH); increasing government healthcare spending; favorable healthcare infrastructure; public healthcare programs and a considerable number of licensing, M&As and co-development deals.

Scope

The overall pharmaceuticals and clinical trials markets in Argentina.

A pharmaceutical market characterization of the Argentine pharmaceutical market, including market size data and forecast clinical trials, healthcare regulations, pricing, and major marketing and distribution channels.
The historic and forecast growth of the clinical trials market in Argentina.
Analysis of the leading segments within the Argentinean pharmaceutical industry.
Key Argentine market drivers and restraints that have a significant impact on the market.
Profiles of the leading companies in the pharma, distribution and CRO sectors.
Key M&A activities, licensing and co-development deals that have taken place between 2004 and 2011.

Reasons to Buy

Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
Devise a better-tailored national strategy through an understanding of the key drivers and barriers of the country’s pharmaceutical market.
Develop key strategic initiatives by understanding the key focus areas of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9

2 Emerging Pharmaceutical Market: Argentina - Introduction 11
2.1 Overview 11

3 Emerging Pharmaceutical Market: Argentina - Industry Characterstics 12
3.1 Market Size and Forecast 12
3.1.1 Overview 12
3.1.2 Revenue Forecast 12
3.1.3 Prescription vs. OTC Drugs 13
3.1.4 Revenue Analysis by Therapy Area 14
3.2 Competitive Landscape 15
3.2.1 Overview 15
3.2.2 Market Share - Domestic vs. Foreign 16
3.2.3 Market Share Analysis 17
3.2.4 Major Domestic Players 18
3.2.5 Major Foreign Players 20
3.3 Pharmaceutical Trade - Forecast 24
3.3.1 Pharmaceutical Exports, Imports and Balance of Trade 24
3.3.2 Exports by Destination 26
3.3.3 Imports by Source 27
3.4 Pharmaceutical Marketing and Distribution 28
3.4.1 Pharmaceutical Distribution System 28
3.4.2 Major Distributors 29
3.5 Clinical Trials 30
3.5.1 Number of Clinical Trials Registered in Argentina 30
3.5.2 Number of Clinical Trials Registered in Argentina - Trend Analysis 31
3.5.3 Number of Registered Clinical Trial Sites per Million Population 32
3.6 Healthcare System in Argentina 33
3.6.1 Public Healthcare 33
3.6.2 Private Healthcare 34
3.7 PESTL Analysis 34

4 Emerging Pharmaceutical Market: Argentina - Macroeconomic Environment 35
4.1 Demographic Analysis 35
4.1.1 Population Size, Growth, and Structure 35
4.1.2 Patient Availability for Major Diseases 36
4.1.3 Forecasts of Major Diseases 38
4.2 National/Domestic Income 43
4.2.1 Annual GDP Growth Rate - Comparative Analysis 43
4.2.2 Gross National Income (GNI) per Capita in Argentina 44
4.3 Expenditure on Health 45
4.3.1 Total Healthcare Expenditure - Trend Analysis 46
4.3.2 Healthcare Expenditure - Comparative Analysis 48
4.4 Healthcare Workforce and Infrastructure 50
4.4.1 Healthcare Workforce 50
4.4.2 Healthcare Infrastructure 53

5 Emerging Pharmaceutical Market: Argentina - Healthcare Regulation 54
5.1 Pharmaceutical Regulation in Argentina 54
5.1.1 National Healthcare Policy Framework in Argentina 54
5.1.2 Intellectual Property Laws and Medicines 54
5.1.3 Generics Law 55
5.1.4 Legal Provisions 55
5.2 Clinical Trial and Drug Approval Process 58
5.2.1 Approval Process for Clinical Trials in Argentina 58
5.2.2 Registration of Drugs 59
5.3 Pricing and Regulation 60
5.3.1 Cost of Medical Treatment 60
5.3.2 Pricing of Medicines 61

6 Emerging Pharmaceutical Market: Argentina - Strategic Consolidations 62
6.1 Overview 62
6.2 Mergers and Acquisitions 63
6.2.1 Deals by Year 63
6.2.2 Deal by Value 64
6.2.3 Top 10 M&A Deals 65
6.3 Licensing Agreements 68
6.3.1 Licensing Agreements by Year 68
6.3.2 Deals by Value 69
6.3.3 Top 10 Licensing Deals 70
6.4 Co-Development Deals 75
6.4.1 Deals by Year 75
6.4.2 Deals by Value 76
6.4.3 Top 10 Co-Development Deals 77

7 Emerging Pharmaceutical Market: Argentina - Contract Research Organizations (CRO) Landscape 81
7.1 Contract Research Organization (CRO) Sector in Argentina 81
7.1.1 Clinical Trial Market Size and Growth 81
7.2 CRO Profiles 82
7.2.1 Abel Santos & Asociados 82
7.2.2 Activa CRO 83
7.2.3 Blanchard & Asociados 84
7.2.4 EGCP 85
7.2.5 Klixar 86
7.2.6 LatinClin 87
7.2.7 MMatiss 88
7.2.8 ECLA 89
7.2.9 Quintiles 90
7.2.10 Covance 91
7.2.11 Charles River 92
7.2.12 INC Research 93
7.2.13 Theorem Clinical Research 94

8 Emerging Pharmaceutical Market: Argentina - Appendix 95
8.1 Market Definitions 95
8.2 Abbreviations 95
8.3 Research Methodology 97
8.3.1 Industry Characteristics 97
8.3.2 Macroeconomic Environment 97
8.3.3 Healthcare Regulations 97
8.3.4 Strategic Consolidations 97
8.3.5 CRO Landscape 97
8.4 Contact Us 98
8.5 Disclaimer 98
8.6 Sources 98

List of Tables

Table 1: Emerging Pharmaceutical Market: Argentina, Revenue Forecast ($bn), 2010-2015 12
Table 2: Emerging Pharmaceutical Market: Argentina, Market Share of Prescription and OTC Drugs, 2010 13
Table 3: Emerging Pharmaceutical Market: Argentina, Market Share of Domestic and Foreign Companies, 2010 16
Table 4: Emerging Pharmaceutical Market: Argentina, Top 10 Pharmaceutical Companies - Market Share Analysis, %, 2009 18
Table 5: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2005-2010 24
Table 6: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2010-2015 25
Table 7: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, 2010 30
Table 8: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, 2005-2010 31
Table 9: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of the Number of Registered Clinical Trial Sites per Million Population in Six Major Countries in Latin America, 2010 32
Table 10: Emerging Pharmaceutical Market, Argentina, Population Forecast (000), 2000-2050 35
Table 11: Emerging Pharmaceutical Market, Argentina, Patient Population (000), 2010 36
Table 12: Emerging Pharmaceutical Market, Argentina, Mortality by Disease Categories (000), 2010 37
Table 13: Emerging Pharmaceutical Market, Argentina, Population Forecast for HIV (000), 2010-2015 38
Table 14: Emerging Pharmaceutical Market, Argentina, Population Forecast for CVD (000), 2010-2015 39
Table 15: Emerging Pharmaceutical Market, Argentina, Population Forecast for Diabetes (000), 2010-2015 40
Table 16: Emerging Pharmaceutical Market, Argentina, Population Forecast for Cancer (000), 2010-2015 41
Table 17: Emerging Pharmaceutical Market, Argentina, Population Forecast for COPD and Asthma (000), 2010-2015 42
Table 18: Emerging Pharmaceutical Market: Argentina, Four Major Pharmaceutical Markets in Latin America, Annual GDP Growth Rate, %, 2010 43
Table 19: Emerging Pharmaceutical Market, Argentina, GNI per Capita, $, 2005-2010 44
Table 20: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure as Percentage of GDP, %, 2005-2009 46
Table 21: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure per Capita, $, 2005-2009 47
Table 22: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, %, 2009 48
Table 23: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Per Capita Expenditure on Health, Argentina, Mexico and BRIC Countries, $, 2009 49
Table 24: Emerging Pharmaceutical Market: Argentina, Number of Healthcare Personnel and Density Per 10,000 Population, 2011 50
Table 25: Emerging Pharmaceutical Market: Argentina, BRIC Countries, Argentina, Comparative Analysis of Density of Healthcare Personnel and per 10,000 Population, 2011 51
Table 26: Emerging Pharmaceutical Market: Argentina, The US, The UK and Brazil, Comparative Analysis of Growth Rate of Principal Investigators, %, 2001-2006 52
Table 27: Emerging Pharmaceutical Market: Argentina, Healthcare Infrastructure and Density Per 10,000 Population, 2011 53
Table 28: Emerging Pharmaceutical Market: Argentina, Number of Hospitals By Province and City, 2011 53
Table 29: Clinical Trials in Argentina, Cost Comparison Argentina Versus the US, $, 2010 60
Table 30: Emerging Pharmaceutical Market, Argentina, Deals by Type (%), 2004-2011 62
Table 31: Emerging Pharmaceutical Market, Argentina, M&A Deals by Year, 2004-2011 63
Table 32: Emerging Pharmaceutical Market, Argentina, M&A Deals by Value, 2004- 2011 64
Table 33: Emerging Pharmaceutical Market, Argentina, Top 10 M&A Deals, $m, 2004- 2011 65
Table 34: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Year, 2004-2011 68
Table 35: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Value (%), 2004-2011 69
Table 36: Emerging Pharmaceutical Market, Argentina, Top 10 Licensing Agreements, 2004- 2011 70
Table 37: Emerging Pharmaceutical Market, Argentina, Co-development Deals by Year, 2004-2011 75
Table 38: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Value (%), 2004-2011 76
Table 39: Emerging Pharmaceutical Market, Argentina, Top 10 Co-Development Deals, 2004-2011 77
Table 40: Emerging Pharmaceutical Market: Argentina, Clinical Trial Market in Argentina, Revenue, $m, 2010-2015 81

List of Figures

Figure 1: Emerging Pharmaceutical Market: Argentina, Revenue Forecast ($bn), 2010-2015 12
Figure 2: Emerging Pharmaceutical Market: Argentina, Market Share of Prescription and OTC Drugs, 2010 13
Figure 3: Emerging Pharmaceutical Market: Argentina, Revenue Analysis by Therapy Area (%), 2010 14
Figure 4: Emerging Pharmaceutical Market: Argentina, Market Share of Domestic and Foreign Companies (%), 2010 16
Figure 5: Emerging Pharmaceutical Market: Argentina, Top 10 Pharmaceutical Companies - Market Share Analysis (%), 2009 17
Figure 6: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2005-2015 24
Figure 7: Emerging Pharmaceutical Market: Argentina, Share of Major Export Destinations of Argentina, %, 2010 26
Figure 8: Emerging Pharmaceutical Market: Argentina, Share of Major Sources of Argentine Imports, %, 2010 27
Figure 9: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Distribution System, 2010 28
Figure 10: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, %, 2010 30
Figure 11: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered - Trend Analysis, 2005-2010 31
Figure 12: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of the Number of Registered Clinical Trial Sites per Million Population in Six Major Countries in Latin America, 2010 32
Figure 13: Emerging Pharmaceutical Market: Argentina, PESTL Analysis 34
Figure 14: Emerging Pharmaceutical Market, Argentina, Population Forecast (000), 2000-2050 35
Figure 15: Emerging Pharmaceutical Market, Argentina, Patient Population (000), 2010 36
Figure 16: Emerging Pharmaceutical Market, Argentina, Mortality by Disease Categories, %, 2010 37
Figure 17: Emerging Pharmaceutical Market, Argentina, Population Forecast for HIV (000), 2010-2015 38
Figure 18: Emerging Pharmaceutical Market, Argentina, Population Forecast for CVD (000), 2010-2015 39
Figure 19: Emerging Pharmaceutical Market, Argentina, Population Forecast for Diabetes (000), 2010-2015 40
Figure 20: Emerging Pharmaceutical Market, Argentina, Population Forecast for Cancer (000), 2010-2015 41
Figure 21: Emerging Pharmaceutical Market, Argentina, Population Forecast for COPD and Asthma (000), 2010-2015 42
Figure 22: Emerging Pharmaceutical Market: Argentina, Four Major Pharmaceutical Markets in Latin America, Annual GDP Growth Rate, %, 2010 43
Figure 23: Emerging Pharmaceutical Market, Argentina, GNI per Capita, $, 2005-2010 44
Figure 24: Emerging Pharmaceutical Market: Argentina, Components of Healthcare Expenditure, %, 2009 45
Figure 25: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure as Percentage of GDP, %, 2005-2009 46
Figure 26: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure per Capita, $, 2005-2009 47
Figure 27: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, %, 2009 48
Figure 28: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Per Capita Expenditure on Health, Argentina, Mexico and BRIC Countries, $, 2009 49
Figure 29: Emerging Pharmaceutical Market: Argentina, Density of Healthcare Personnel Per 10,000 Population, 2011 50
Figure 30: Emerging Pharmaceutical Market: Argentina, BRIC Countries, Argentina, Comparative Analysis of Density of Healthcare Personnel and per 10,000 Population, 2011 51
Figure 31: Emerging Pharmaceutical Market: Argentina, The US, The UK and Brazil, Comparative Analysis of Growth Rate of Principal Investigators, %, 2001-2006 52
Figure 32: Clinical Trials in Argentina, Clinical Trial Regulation Approval Process, 2011 58
Figure 33: Emerging Pharmaceutical Market, Argentina, Deals by Type (%), 2004-2011 62
Figure 34: Emerging Pharmaceutical Market, Argentina, M&A Deals by Year, 2004-2011 63
Figure 35: Emerging Pharmaceutical Market, Argentina, M&A Deals by Value (%), 2004- 2011 64
Figure 36: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Year, 2004-2011 68
Figure 37: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Value (%), 2004-2011 69
Figure 38: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Year, 2004-2011 75
Figure 39: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Value (%), 2004-2011 76
Figure 40: Emerging Pharmaceutical Market: Argentina, Clinical Trial Market in Argentina, Revenue, $m, 2010-2015 81
Figure 41: Emerging Pharmaceutical Market, Argentina, Abel Santos & Asociados, Company Profile, 2011 82
Figure 42: Emerging Pharmaceutical Market, Argentina, Activa CRO, Company Profile, 2011 83
Figure 43: Emerging Pharmaceutical Market, Argentina, Blanchard & Asociados, Company Profile, 2011 84
Figure 44: Emerging Pharmaceutical Market Argentina, EGCP, Company Profile, 2011 85
Figure 45: Emerging Pharmaceutical Market, Argentina, Klixar, Company Profile, 2011 86
Figure 46: Emerging Pharmaceutical Market, Argentina, LatinClin, Company Profile, 2011 87
Figure 47: Emerging Pharmaceutical Market, Argentina, Mmatiss, Company Profile, 2011 88
Figure 48: Emerging Pharmaceutical Market, Argentina, ECLA, Company Profile, 2011 89
Figure 49: Emerging Pharmaceutical Market, Argentina, Quintiles, Company Profile, 2011 90
Figure 50: Emerging Pharmaceutical Market, Argentina, Covance, Company Profile, 2011 91
Figure 51: Emerging Pharmaceutical Market Argentina, Charles River, Company Profile, 2011 92
Figure 52: Emerging Pharmaceutical Market, Argentina, INC Research, Company Profile, 2011 93
Figure 53: Emerging Pharmaceutical Market, Argentina, Theorem Clinical Research, Company Profile, 2011 94

Related Reports

Home Healthcare Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

Oct 22, 2012 | By - Transparency Market Research

This report is an effort to identify factors, which will be the driving force behind the home healthcare market and sub-markets in the next few years. The report provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the home healthcare industry in terms of...

Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

Oct 1, 2012 | By - GBI Research

Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth GBI Research, the leading business intelligence provider has released its latest research report, Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support...

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

Nov 1, 2012 | By - GBI Research

Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market GBI Research, the leading business intelligence provider, has released its latest research, Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable...

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

Sep 30, 2012 | By - GBI Research

Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans GBI Research, the leading business intelligence provider has released its latest research report, Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans. The report focuses on the key insights into the biodefense...

e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

Jul 31, 2012 | By - GBI Research

GBI Research, the leading business intelligence provider, has released its latest research, e-Clinical Trial Solutions Market to 2018 Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies, which provides key data and analysis of the major factors affecting the market for eClinical trial solutions in the...

Upcoming Reports:

Knee Implants Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018

By - Transparency Market Research

Knee implant procedures are done when a patient has knee pain, a traumatic injury or a disability from rheumatoid arthritis, or osteoarthritis. In the surgical process, a surgeon implants the device (artificial device) and replaces the damaged knee with it. There are many different types of implants - which are made of metal alloys, strong plastic parts or ceramic material. The knee implants market will grow due to factors such as increase in the rate of age related diseases like osteoporosis and arthritis, diabetes, obesity, ageing population and injuries related...

Hepatitis C Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018

By - Transparency Market Research

The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on hepatitis C virus. In future, the growth of HCV market is expected to come from emerging markets of Asia Pacific, Middle East, and Latin America as these regions are likely to register maximum number of HCV incidences due to increasing...

Haptic And Touch Technology Market - Global Industry Analysis, Market Size, Share, Growth, And Forecast, 2012 - 2018

By - Transparency Market Research

Haptic technology is mechanical simulation used to create the sense of touch in computer and other electronic devices by using different forces, motion, and vibration. The haptic and touch screen technology market observed significant growth in the last few years with growing application in Smartphone devices, navigation devices, portable gaming devices, digital cameras, media players, tablet computers, and e-readers. The global haptic and touch technology market is expected to grow at a CAGR of 11% from 2012 to 2018. North America represents the largest region for the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-618-1030
Email: sales@researchmoz.com

Select License type:

Share this report

Scoop.it

Latest Reports

Sep 14, 2012

The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...

Now At-Home TB Diagnosis Looks Possible

Sep 14, 2012

According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...

China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects

Sep 14, 2012

Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...

Battling against flu, vaccination necessary for health workers

Sep 14, 2012

To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...

Japan to Cut Import Duties on Indian Generic Drugs Imports

Sep 14, 2012

The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...